The phenotypic effect of perturbing a gene's activity depends on the activity level of other genes, 29 reflecting the notion that phenotypes are emergent properties of a network of functionally interacting 30 genes. In the context of cancer, contemporary investigations have primarily focused on just one type of 31 functional genetic interaction (GI) -synthetic lethality (SL). However, there may be additional types of 32 GIs whose systematic identification would enrich the molecular and functional characterization of cancer.
. GIs are of particular interest in 46 cancer because the dependence of one gene's phenotypic effect on the activity of another gene provides 47 opportunities for selective killing of cancer cells (Kaelin, 2005) and the interaction partners of drug 48 targets can buffer their effects leading to resistance (Fong et al., 2015; Miyamoto et al., 2015) . 
64
Indeed, previous investigations have shown that the overall numbers of functionally active SLs and SDLs 65 in a given tumor sample are highly predictive of patient survival (Megchelenbrink et al., 2015) . These 66 three interaction types however represent just the 'tip of the GI iceberg', as there are many additional 67 types of GI that can be defined at a conceptual level, and whose systematic exploration may have 68 important functional ramifications for cancer therapy.
69
Here we present a novel data-driven computational pipeline, called "EnGIne" (Encyclopedia of 70 clinically significant GIs in cancer). We applied EnGine to analyze 5,288 TCGA samples (Methods) of 18 71 different cancer types, identifying clinically significant GIs of 12 distinct types. Using drug response data 72 from TCGA and molecular drug target information, we show that the detected GIs are associated with 73 response to therapy by specific drugs. Their activation patterns can account for the tissue-specificity of 74 known driver genes and stratify breast cancer into clinically relevant subtypes. In sum, EnGIne 75 substantively expands the current knowledge of genetic interactions in cancer, laying a strong conceptual 76 and computational foundation for future studies of additional GI types.
78

Results
79
Overview of the Encyclopedia of Genetic Interactions (EnGIne) Pipeline
80
The overall EnGine pipeline is summarized in Fig. 1 and the technical details are provided in the Methods 81 section. Given a large set of tumor transcriptomes ( Fig. 1A) , we first partition the expression level of each 82 gene into low, medium and high, following our previous approach to identify SL interactions (Lee et al., 83 2018). Thus, for a pair of genes, there are 9 = 3 × 3 combinations, or bins, of possible co-activity states 84 for the two genes ( Fig. 1B) . For a given ordered pair of genes, each tumor sample maps to exactly one of 85 the 9 bins. Our goal is to identify GI pairs of the form 
90
1C; note that for most gene pairs, there may not be any bin Supplementary Fig. S2A ).
158
Additionally, we ascertained that the inferred GIs are not dominated by correlated gene expression 159 patterns (Supplementary note 2). 
Differential activity of drug target GIs between responders and non-responders
219
Aiming to test the ability of EnGIne inferred GIs to predict drug response, we applied EnGIne to identify 220 GIs based only on TCGA samples that do not have drug response information, and tested the predicted 221 GIs' ability to discriminate responders from non-responders in the 'unseen' TCGA samples where the 222 drug response information is available (Methods). Notably, because the considered drugs are inhibitory, it 223 suffices to focus on GI bins 1, 2, and 3, where one of the genes (the drug's target) has low activity. For a 224 given drug and cancer type having data on responders and non-responders, we analyzed the GIs involving 225 each of the drug targets (identified via target-specific FDR; Methods). We then tested whether the 226 frequencies of GI activation in responders and the non-responders are significantly different using a 227 Fisher exact test (Fisher, 1922 Gemcitabine, Lomustine, and Paclitaxel exhibit differential GI activation for most GI types (aggregate P-243 values ranging from 4E-16 to 2E-11). We also explored the most differentially activated individual GIs.
244
Imposed an empirical FDR threshold of 0.01 on the Fisher test P-value yielded 521 GIs for the 12 drug-245 cancer type combinations (Methods, Supplementary Table S2 ). Individual genes comprising the 521 GIs 246 are closer to each other in the PPI network relatively to shuffled pairs (Wilcoxon P < 0.001, Methods) and 247 have a significantly increased number of direct PPI interactions between them (Fisher P < 0.02, Methods).
248
As an illustrative test case, we explored the GIs associated with the response to Paclitaxel, in 249 TCGA Head and Neck Squamous Cell Carcinoma (HNSC) cohort. Paclitaxel inhibits the proteins 250 encoded by BCL2, TUBB1, and MAP based on DrugBank (Law et al., 2014) . We identified a GI 251 10 involving the inactivation of BCL2 (known to suppress apoptosis, indirectly inhibited through 252 phosphorylation (Ruvolo et al., 2001) ) and the over-activation of ITPR1 (Inositol 1,4,5-trisphosphate 253 receptor type 1, also known as IP3 receptor type 1), negatively affecting tumor fitness (GI type -3).
254
Interestingly, our analysis shows that this GI is functionally active among the responders at a significantly 255 higher ratio than among non-responders (odds-ratio ≈ 11.1). The interaction between ITPR1 and BCL2 is tumor suppressors whose effects are likely to be restricted to specific cancer types, based on preferentially 273 high mutation rates in those cancer types, including breast, bladder, and gastric cancer (Methods, 274 Supplementary Table S3 ). For each cancer driver, we assigned a risk score to each patient by aggregating 275 functionally active GIs involving the driver gene defined using target-specific FDR (Methods); for 276 oncogenes, only the bins with high oncogene activity and for tumor suppressors, only the bins with low 277 tumor suppressor activity were considered (Methods). We hypothesized that for a cancer gene, the risk 278 score will be greater in tissues where the cancer gene is implicated relative to other tissues. Indeed, for 15 279 out of 35 (~43%; 5 oncogenes and 10 tumor suppressors) driver genes, the observations are consistent 280 with our hypothesis (Wilcoxon rank-sum test, FDR < 0.1, Supplementary Table S3 ).
281
For instance, HLF, a bZIP transcription factor, has been linked to lung and breast cancer based on 282 its significantly greater missense mutation frequency in those cancer types (Gonzalez-Perez et al., 2013).
283
We observed a significant difference (FDR < 1.07E-12) in GI activation risk score for breast and lung 284 cancer relative to the other tissues. Specifically, we found that positive GIs are preferentially activated in 285 11 these two tissues while negative GIs are preferentially activated in the other tissues, consistent with the 286 increased tumor fitness in these two foreground tissues (Fig. 3C,D) . Overall, these results suggest that 287 cancer type-specific effects of many driver genes may be explained by their tissue-specific GI network Supplementary Fig. S7A ). Upon closer inspection of the distributions of 320 known breast cancer subtypes in these clusters ( Supplementary Fig. S7B ) we merged two of the clusters, 321 thus yielding 9 clusters for further analyses.
322
Kaplan-Meier curves (Fig. 4A ) and statistical analysis show that the 9 clusters have distinct 323 survival characteristics with an overall mean hazard ratio (HR) difference of 1.94 (P-value below the 324 lowest reportable threshold and shown as 0). The distinct survival characteristics are consistent with 325 analysis performed using the full 71,946 GI network ( Supplementary Fig. S7C ). Supplementary Fig. S8A 
337
We find the GI based approach to provide improved survival predictive value over the classical 338 histopathological ones (Fig. 4C,D) . There are two situations in which the GI-based clustering leads to a 339 different classification of patients for survival analysis: (1) cases where known histopathological breast 340 cancer subtypes are split across multiple GI-based clusters (e.g. Luminal B across clusters 1, 2 and 8), and 341 conversely (2), cases where one GI-based cluster harbors multiple known histopathological subtypes (e.g. 342 cluster 2 contains Her-2 and Luminal B subtypes). In the former case, we find that the 1989 Luminal B 343 tumors that are split across different GI-based clusters exhibit statistically significant (P < 7.14E-06) 344 distinct survival trends (Fig. 4C) , supporting the GI approach in separating the Luminal B tumors.
345
Likewise, in the latter case, we find that the survival trends of Her-2 and Luminal B histopathological 346 subtype samples that are assigned to the same GI-based cluster 8 do not show a significant difference (P < 347 0.203) in their survival trends ( Fig. 4D ), suggesting that the GI-based stratification may in some instances 348 provide better survival prognosis relative to histopathology-based stratification. We systematically 349 identified 6 additional instances of the above two scenarios where (1) a known tumor histopathological 350 subtype was split across multiple GI-based clusters or (2) multiple known histopathological subtypes 351 were assigned to the same GI-based cluster (and each cluster has at least 30 samples). In each instance of 352 the first kind we tested for statistically significant differences in survival and in each instance of the 353 second kind we tested for lack thereof. As shown in Supplementary Fig. S9 , in 5 out of 6 instances we 354 found that the GI-based clusters provided a more accurate survival prognosis. In contrast, we identified 4 355 cases of the second kind in the original METABRIC clusters (Curtis et al., 2012) and found that none of 356 their survival trends were significantly different ( Supplementary Fig. S10 ). Thus, these results 357 demonstrate that the GI approach performs better than clustering based on histopathological subtypes or 358 METABRIC clustering based on gene expression profiles, in terms of survival prognosis.
359
To explore potential mutational basis of the GI-based clusters in another way, we assessed 360 whether the samples in GI-based clusters harbor distinct mutations patterns. We identified 196 genes 361 ( Supplementary Table S4 ) with significantly greater mutation frequency in one or more of the clusters, 362 relative to their overall mutation frequency in breast cancer (Methods). Fig. 4E shows the mutational 363 frequency profiles of these genes across the 9 clusters. Overall, the differentially mutated genes across the 364 GI based clusters include 10 cancer drivers: CDK12, CDKN1B, DNAJB1, ERBB2, EXT2, FCGR2B, 365 FNBP1, HOXC13, PDGFRB, and SEC24D. A more detailed discussion of the potential biological 366 significance of some of these mutations is provided in the Supplementary Results. We note that no 367 mutation data was used in the GIs inference via EnGIne. (Szczurek et al., 2013) defined the high (low) state as mRNA expression higher than the 80 th quantile 416 (lower than the 20 th quantile, respectively). We chose to partition gene activity into 3 quantiles of low, 417 medium, and high activity levels within cancer samples. We have shown the robustness of the detected 418 GIs (Supplementary note 1). Besides its simplicity and being non-parametric, our strategy naturally 419 allows us to search for cases where even the normal (or medium) levels of expression of a gene may be 420 associated with fitness effects, depending on the states of other genes (e.g, bins 4 and 7).
421
Identifying pairwise gene interaction is only a first step toward capturing the true complexity of 422 cellular networks. Future work can go beyond the 12 basic GI types studied here to investigate more 423 complex GI types that involve different compositions of these basic types; for instance, a given drug response analysis, to consider only gene inactivation mechanism, we excluded those drugs whose 439 DrugBank mechanism of action label is either potentiator, inducer, positive allosteric modulator, 440 intercalation, stimulator, positive modulator, activator, partial agonist, or agonist.
441
We performed gene expression binning specifically for each combination of cancer type, race and gender. As shown in Fig. 1 , we divided the range of each gene's expression across tumor samples into 3 equal-460 sized bins that correspond to the 3 activity states: low, medium and high expression. Given a gene pair, 461 18 each tumor sample is thus mapped into one of the 9 joint activity states of the two genes. The choice of 462 dividing a gene's activity into three classes, while somewhat arbitrary, was made in consideration of 463 interpretability of functional states and robustness of inference. However, to account for differences in 464 expression distributions across clinical and demographic confounders, we apply a subpopulation specific 465 binning approach. We considered the following categorical confounders: cancer type, race, and gender.
466
We considered the combination of confounder states for which there were at least 100 tumor samples 467 ( Supplementary Table S5 ). Our binning is thus not confounded by various clinical and demographic 468 variables.
469
The GI pipeline consists of three steps that successively refine the predictions to arrive at high-confidence 470 set of predicted GIs. As such, the number of all pair-wise combinations of genes is excessively large to 471 apply a comprehensive Cox regression model. For the principal analysis shown in the manuscript, specific 472 parameter thresholds were chosen to make the subsequent analysis tractable, but users of the GI pipeline 473 may choose other thresholds. To inform such decisions, we did a robustness analysis of the parameter 474 settings with a smaller input set of gene pairs (Supplementary note 1).
475
Step 1: Log-Rank. In the first step, for each of the ~163 million gene pairs, say (x,y), we compute the 476 Log-rank statistics (Harrington and Fleming, 1982) for genomic-stability and tumor purity as a potential confounder is described in Supplementary note 4. Supplementary Fig. S5 ).
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543
To compare the GI-based survival prediction with the individual gene approach, we implemented 544 an analogous scheme for individual genes where the gene expression values were discretized into 3 545 expression levels (low, medium and high), and the discretized representation was used as a predictor 546 variable in a controlled Cox regression model to obtain the significance (p-value) of each gene with 547 respect to survival prediction. The most significant predictors (top 5%) were chosen and precisely used as 548 described for the GIs survival prediction procedure. An analogous procedure was used to estimate the 549 prediction accuracy based on both individual gene effects and GIs.
550
Identifying gene target(s)-specific GIs
551
To investigate the GIs involving specific genes of interest (e.g., one or more target genes inhibited by a 552 drug), we used a modified gene set-specific FDR approach. For a set of one or more genes X, we compare 553 the GI significance (Cox regression p-value) of GIs involving any gene in X across the quadruples 554 derived from step 2 (Molecular enrichment/depletion). We defined significant GI interactions as those 555 21 where the GI significance is more extreme than (lower p-value, higher quantile) the 90 th quantile of 556 shuffled GIs involving any member of X. 557
Characterization of differential GI activation between drug-response groups
558
We retrieved the drug response data as explained in the first subsection of Methods; some patients have 559 response information, and some do not. We inferred the GIs involving each drug's known target gene 560 based on the TCGA samples that do not have that drug's response information to avoid circularity and 561 filtered based on FDR restricted to the target-specific GIs (using target-specific FDR above (Berkson, 1978) , we tested 568 whether the overall distribution of the obtained odds-ratios are lower than those obtained using randomly 569 shuffled drug-response labels, using one-sided Wilcoxon tests (Wilcoxon, 1945) . We thus obtained a p-570 value for each drug-cancer type pair, segregated by GI type.
571
Then, for each gene pair in the inferred GIs list and, as a control, in a shuffled list of size 10x as 572 the original GIs list size, we computed the distance between the genes in the PPI network (Schaefer et al., 573 2012). We then used one-sided Wilcoxon tests (Wilcoxon, 1945) to assess whether GI gene pairs are 574 closer to each other than random expectation. Alternatively, we also compare the number of directly GI 575 gene pairs having direct interaction using one-sided Fisher's exact test (Fisher, 1922 involving this gene (target-specific FDR). We further excluded genes with 5 or fewer interactions or with 584 300 or fewer samples where they are expressed, reducing the set of genes of interest to 20 tumor 585 suppressors and 15 oncogenes spanning 10 cancer types ( Supplementary Table S3 ). For a gene, a sample-586 specific risk score was calculated based on the functionally active GI partners of the gene (as above for 587 22 the drug response analysis above), but only considering high activity bin for oncogenes and low-activity 588 bins for tumor suppressors. For each gene, the cancer types are partitioned into affected types (cancer 589 types affected by the driver) and the other unaffected cancer types. Using a one-sided Wilcoxon rank-sum 590 test, we tested for higher risk score in the samples in the affected cancer type in comparison to those in 591 unaffected types. After correcting for multiple hypotheses testing, 15 out of the 35 (~43%) driver genes 592 were found to have significant tissue-specific GI-based risk score (FDR q-value < 0.1, Supplementary 593 Table S3 ).
595
Breast cancer tumor stratification
596
We represent a tumor sample as a vector indicating the functional activity status of each predicted GI.
597
This provides a survival-cognizant alternative to the widely-used gene expression profile representation of 598 a sample. We used this representation to partition the METABRIC (as well as independently for TCGA) 599 breast cancer patients into clusters using Non-Negative Matrix Factorization (NMF using the brunet 600 algorithm and assigning each sample to the cluster with the highest weight) (Lee and Seung, 2000; 601 Paatero and Tapper, 1994) , which has suitable statistical properties and has been shown to be effective in 602 a variety of contexts (Lee and Seung, 1999) . Since NMF requires a predetermined number of clusters, we 603 performed the analysis for 2-15 clusters, and assessed their fitness using Dunn's index (Dunn †, 1974) , 604 which quantifies compactness within and separation across clusters. The hazard-ratio significance values 605 were computed for each pair of clusters, while the p-values were generated using multi-class log-rank 606 test. For comparison purposes, to match our estimated clusters' sizes to previously published METABRIC 607 cluster sizes (~900 samples), we constrained the number of samples in each cluster to the 1000 samples 608 that were found to be most highly associated with the cluster. Each cluster's GI profiles were constructed 609 as follows. Our clustering approach -NMF, assigned each GI to a single cluster. For each cluster, and for 610 each of the 12 GI-types (6 bins in Fig. 1 and the two directional effects on survival), we obtain the 611 frequency of GIs of that type, relative to all GI assigned to the clusters.
612
Mutation frequency analysis was performed on the TCGA clusters. We defined the gene-wise 613 mutation frequency as the fraction of samples in the cluster in which the gene has a mutation predicted to 614 be deleterious as explained in the next paragraph. Then, we tested whether the mutation frequency 615 distribution of each gene differs significantly across clusters using Chi-square tests. The genes with 616 significant Chi-square statistic (FDR q-value < 0.1) were then used to illustrate the mutational profiles of 617 the clusters.
23
Each mutation's predicted effect on the protein function was obtained from the cBioPortal 619 repository. Out of the 196 differentially mutated genes, 138 genes had matching extended mutation 620 information indicating their SIFT (sorts intolerant from tolerant amino acid substitutions) and PolyPhen 621 (polymorphism phenotyping) predictions. We calculated a gene-wise fraction of mutations predicted to 622 have a significant effect on the protein, separately for SIFT and PolyPhen.
623
The breast cancer subtypes were derived using the widely accepted PAM50 algorithm ( 
